TARGA
MANAGEMENT TEAM
Gary D. Aronson, M.B.A., J.D.
Chief Executive Officer, Emeritus
Member, Board of
Directors
- Targa Chief Executive
Officer and Co-Founder
- 18
Years experience in biotechnology start-ups &
financing
- Work
related to 10 Biotechnology start-ups and early-stage
companies
- Co-founder &
President, DepoTech Corp. sustained release injectable drug
delivery company
- Broad biopharma
experience including biotechnology research reagents, anti-cancer
drugs, pain drugs, drug delivery systems, rational drug design,
drug development, human gene therapy and regenerative
medicine
In a
prior position as president of DepoTech Corp., Mr. Aronson had overall
responsibility for supervising the pre-clinical and clinical
development of several new sustained-release formulations in a number
of therapeutic fields, including DepoCyte™, an anti-cancer drug
now on the market, DepoMorphine™ a pain medication whose NDA has
now been submitted for U.S. FDA approval and DepoBupivacaine™, a
pain medications currently in advanced human clinical trials, and
several other formulations in various stages of development.
Randy Berholtz,
J.D.
Randy Berholtz is Vice President, Business Development
for ACON Laboratories, a Chinese-based medical device and diagnostics
manufacturer. Prior to that position he was Chief Operating Officer for
IngleWood Ventures, a San Diego based life sciences venture capital
fund and prior to that was Senior Director, Business Development for
Nanogen, Inc., a San Diego genetic products company. He is an Advisory
Board member of the Keck Graduate Institute of Applied Life Sciences at
the Claremont Colleges and is a member of the Life Science Angels of
Menlo Park. He received a BA summa cum laude from Cornell University, a
masters degree from Oxford University where he was a Rhodes Scholar and
a law degree from the Yale Law School.
|
